|
|
Q-Med Ab - Comparative Business Analysis Snapshot
Business Description
Q-Med Ab. The Group's principal activities are the manufacturing, marketing and selling of medical implants based on the company's patented technology NASHA (Non-Animal Stabilized Hyaluronic Acid) to physicians, clinics and institutions. The Group operates through two segments: Esthetics and Hospital healthcare. The Esthetics segment manufactures products for the filling out of wrinkles and for the contouring of lips using Restylane. The Hospital healthcare segment manufactures products, which include ZUIDEX for the treatment of stress urinary incontinence in women, DEFLUX for the treatment of VUR (a malformation of the urinary bladder in children) and DUROLANE for the treatment of osteoarthritis of the knee and hip. The Group operates globally.
Competitor Analysis
This analysis compares Q-Med Ab with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
|
|
|
|
